BIO Responds To Miller

Henry Miller's essay regarding Environmental Protection Agency (EPA) regulation of plant pesticides and BIO's position ("BIO's 'Cooperation' With Regulators Deals A Blow To Competition," The Scientist, Oct. 2, 1995, page 12) is replete with half-truths and makes a serious allegation that must be answered. Miller speaks of both monolithic regulation by EPA and an industry in lockstep with the regulators. Had he read the EPA proposal and the BIO response, he would have been much better informed.

Written byCarl Feldbaum
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Contrary to what Miller writes, EPA has not proposed to regulate whole plants, only certain pesticidal substances produced in plants. EPA developed this proposal over a five-year period and sought broad public input at several meetings of its Science Advisory Panel. We can quibble about the definition of what should fall within EPA's scope, but the agency has broad legal regulatory authority under the pesticide statute. BIO filed 19 pages of comment last February. We argued that EPA should narrow the focus of this oversight to only those pesticidal substances that have a toxic mode of action or are foreign to the food supply. This position was approved by all of the BIO member companies, large and small, that are developing new crops through biotechnology. This was not a position dictated by one or two companies, as Miller asserts.

EPA is responsible for the registration of a wide variety of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies